Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr;53(4):1657-9.
doi: 10.1128/AAC.00998-08. Epub 2009 Feb 2.

In vitro activities of fluconazole and voriconazole against clinical isolates of Candida spp. determined by disk diffusion testing in Turin, Italy

Narcisa Mandras  1 , Vivian Tullio, Valeria Allizond, Daniela Scalas, Giuliana Banche, Janira Roana, Francesca Robbiano, Giacomo Fucale, Aurelio Malabaila, Anna Maria Cuffini, Nicola Carlone
Affiliations

In vitro activities of fluconazole and voriconazole against clinical isolates of Candida spp. determined by disk diffusion testing in Turin, Italy

Narcisa Mandras et al. Antimicrob Agents Chemother. 2009 Apr.

Abstract

The in vitro activities of fluconazole and voriconazole against 1,024 clinical isolates of Candida spp. were determined by the agar disk diffusion test using the Clinical and Laboratory Standards Institute (CLSI) M44-A guidelines. The results of this investigation demonstrated the broad-spectrum in vitro activity of voriconazole, relative to that of fluconazole, against yeasts tested, in particular fluconazole-resistant isolates, such as Candida krusei that showed high susceptibility to voriconazole. The situation in Turin, Italy, is quite similar to that of the rest of Italy, reflecting the worldwide trend.

PubMed Disclaimer

References

    1. Borg-von Zepelin, M., L. Kunz, R. Rüchel, U. Reichard, M. Weig, and U. Gross. 2007. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. J. Antimicrob. Chemother. 60:424-428. - PubMed
    1. Clinical and Laboratory Standards Institute. 2007. Zone diameter interpretive standards, corresponding minimal inhibitory concentration (MIC) interpretive breakpoints, and quality control limits for antifungal disk diffusion susceptibility testing of yeasts; 17th informational supplement. CLSI M44-S2. Clinical and Laboratory Standards Institute, Wayne, PA.
    1. Gualco, L., E. A. Debbia, R. Bandettini, L. Pescetto, A. Cavallero, M. C. Ossi, A. M. Schito, and A. Marchese. 2007. Antifungal resistance in Candida spp. isolated in Italy between 2002 and 2005 from children and adults. Int. J. Antimicrob. Agents 29:179-184. - PubMed
    1. Guinea, J., M. Sánchez-Somolinos, O. Cuevas, T. Peláez, and E. Bouza. 2006. Fluconazole resistance mechanisms in Candida krusei: the contribution of efflux-pumps. Med. Mycol. 44:575-578. - PubMed
    1. Hazen, K. C., E. J. Baron, A. L. Colombo, C. Girmenia, A. Sanchez-Sousa, A. Del Palacio, C. deBedout, D. L. Gibbs, and the Global Antifungal Surveillance Group. 2003. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. J. Clin. Microbiol. 41:5623-5632. - PMC - PubMed

Publication types

LinkOut - more resources